ATX ASX News

11 August 2024

Amplia Receives R&D Tax Rebate Totalling $3.2 Million

Amplia Therapeutics secures a $3.2 million R&D tax refund for its FAK inhibitor research.

Amplia Therapeutics R&D Tax Rebate Stock Market News Pharmaceutical Industry

Posted on: 11/08/2024

Read More

5 August 2024

Additional Patient Response in Pancreatic Cancer Trial

Fourth patient shows sustained reduction in tumor size in Amplia's pancreatic cancer trial.

Amplia Therapeutics Pancreatic Cancer Clinical Trials Narmafotinib Stock Market News

Posted on: 05/08/2024

Read More

25 July 2024

Sustained Reduction in Tumour Size Seen In Pancreatic Trial

Amplia Therapeutics sees sustained tumor size reduction in Phase 2a pancreatic cancer trial.

Amplia Therapeutics Pancreatic Cancer Clinical Trials Biopharmaceuticals Stock Market News

Posted on: 25/07/2024

Read More